Key Takeaways ACAD posted Q4 EPS of 16 cents, topping estimates, as revenues rose 9% to $284M.Nuplazid sales rose 7% to $174.4M, while Daybue climbed 13% to $109.6M.ACAD guides 2026 revenues of $1.22-$1.28B; EU review of trofinetide faces likely CHMP rejection.Acadia Pharmaceuticals (ACAD) reported fourth-quarter 2025 earnings per share (EPS) of 16 cents (excluding tax benefit), which beat the Zacks Consensus Estimate of 12 cents. In the year-ago quarter, the company had reported adjusted EPS of 17 cents.In ...

For the quarter ended December 2025, Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million, up 7.6% over the same period last year. EPS came in at $0.68, compared to $0.70 in the year-ago quarter.The reported revenue represents a surprise of +9% over the Zacks Consensus Estimate of $140.02 million. With the consensus EPS estimate being $0.42, the EPS surprise was +60.95%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

It’s no secret that prescription drug costs in the United States are steep. As part of its goal to rein in those costs, the Trump administration launched TrumpRx in early February. Americans can use the TrumpRx platform to search for discounted prices on prescription drugs. President Trump spoke about the program at Tuesday’s State of the Union address, saying, “Americans, who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs, will now pay the lowe ...

It’s no secret that prescription drug costs in the United States are steep. As part of its goal to rein in those costs, the Trump administration launched TrumpRx in early February. Americans can use the TrumpRx platform to search for discounted prices on prescription drugs. President Trump spoke about the program at Tuesday’s State of the Union address, saying, “Americans, who have for decades paid by far the highest prices of any nation anywhere in the world for prescription drugs, will now pay the lowe ...

Key Takeaways Amarin reported Q4 adjusted EPS of 1 cent, beating estimates despite a 21% revenue decline.AMRN's Vascepa sales fell 23% year over year, hit by lower U.S. prices and Europe's Recordati shift.Amarin achieved positive Q4 cash flow and targets $70M in annual cost savings.Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of a loss of $1.27. The company had reported an adjusted loss of 2 cents per share in t ...

Key Takeaways Ionis beat Q4 estimates, but shares fell 5% on a softer-than-expected 2026 revenue outlook.Commercial revenues jumped 64%, driven by Tryngolza sales and Dawnzera's first full quarterIonis guides 2026 revenues of $800M-$825M, below estimates, citing slower new drug uptakeIonis Pharmaceuticals (IONS) reported fourth-quarter 2025 adjusted loss per share of $1.14, narrower than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago period, the company had incurred an adjusted loss of 43 ...

Core Insights - SHINE Technologies has raised $240 million in equity funding to advance its commercial fusion technology [1] - The company appointed Dr. Patrick Soon-Shiong to its board, enhancing its leadership in fusion and cancer treatment [1] - The funding round was led by NantWorks, with participation from several notable investors, indicating strong investor confidence [1] Company Developments - SHINE's commercial fusion technology includes neutron testing for defense and aerospace, and radioisotopes for cancer therapies [1] - The investment marks the beginning of SHINE's next growth phase, focusing on recycling used nuclear fuel and commercial fusion energy production [1] - SHINE has raised over $1 billion in total funding, reflecting sustained investor confidence in its path to fusion energy [1] Strategic Partnerships - A strategic partnership with NantWorks includes priority access arrangements for Lu-177 supply, aimed at advancing targeted cancer treatment [1] - Dr. Soon-Shiong's investment of $150 million is part of this partnership, emphasizing the alignment of SHINE's technology with cancer treatment goals [1] Industry Impact - SHINE operates one of the largest Lu-177 production facilities in North America, contributing to advancements in cancer treatment [1] - The company's long-term goal is to commercialize fusion energy while impacting healthcare and sustainable energy sectors [1]

Core Insights - United Therapeutics (UTHR) reported Q4 2025 earnings per share (EPS) of $7.70, exceeding the Zacks Consensus Estimate of $6.78, with a year-over-year increase of 24% driven by higher product sales [1][7] - The company anticipates "double-digit revenue growth" in 2026 and aims for a $4 billion annualized revenue run rate in the second half of 2027 [2][3] Financial Performance - Q4 revenues were $790.2 million, missing the Zacks Consensus Estimate of $805 million, but reflecting a 7.3% year-over-year growth, primarily from Tyvaso and Orenitram [2] - For the full year 2025, total revenues reached $3.18 billion, an 11% increase from 2024, with net earnings of $27.86 per share compared to $24.64 in 2024 [11] Product Sales Breakdown - Combined sales of Tyvaso products were $464.3 million, up 12% year over year, although they fell short of the Zacks Consensus Estimate of $488 million [4] - Tyvaso DPI generated $338.6 million in revenue, a 24% increase year over year, aided by enhanced commercialization efforts [5] - Sales of nebulized Tyvaso were $125.7 million, down 12% due to lower volumes [8] - Orenitram sales rose 12% to $121.2 million, while Remodulin sales declined 5% to $128 million, and Unituxin sales decreased 8% to $62.3 million [8] Expenses - Research and development expenses were $139.5 million, up 4.3% year over year, reflecting increased clinical development costs [9] - Selling, general, and administrative expenses rose 13.1% to $190.6 million, driven by higher consulting and personnel costs [9] Pipeline Developments - Key phase III programs include Tyvaso for chronic fibrosing interstitial lung disease and oral ralinepag for PAH [12] - The TETON-2 study showed clinical benefits in idiopathic pulmonary fibrosis patients, with management believing it could expand Tyvaso's therapeutic reach [13] - The company is also conducting the TETON-1 study and plans to meet with the FDA to expedite regulatory review if results are favorable [14] - Top-line data from the ADVANCE OUTCOMES study for ralinepag is expected in the first half of 2026 [15]

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Co ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation Q4 and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation we ...